{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T09:47:03Z","timestamp":1782899223312,"version":"3.54.5"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Immune checkpoint inhibitors are widely used in the treatment of malignant tumors. Although the incidence rate of type 1 diabetes induced by these inhibitors is low, the damage to pancreatic \u03b2 cells is irreversible and the treatment effect of steroids is poor, which requires clinical attention. This article reports a case of a 69-year-old patient with poorly differentiated adenocarcinoma of the stomach and colon who developed this disease during treatment with Sintilimab combined with the SOX regimen. After insulin treatment, her blood glucose levels gradually stabilized. Based on the literature, we explore the pathogenesis, diagnostic difficulties, and current treatment status centered around insulin replacement therapy. We emphasize the need for clinicians to strengthen blood glucose monitoring during treatment with immune checkpoint inhibitors, identify symptoms early, and optimize diagnosis and treatment to improve patient prognosis.<\/jats:p>","DOI":"10.3389\/fendo.2026.1881986","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T08:56:06Z","timestamp":1782896166000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Type 1 diabetes mellitus induced by sintilimab: a case report and related case literature analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Hao","family":"Su","sequence":"first","affiliation":[{"name":"Department of Oncology, Binzhou Medical University Hospital","place":["Binzhou, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Oncology, Binzhou Medical University Hospital","place":["Binzhou, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huayu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Binzhou Medical University Hospital","place":["Binzhou, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mianli","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, Binzhou Medical University Hospital","place":["Binzhou, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Geng","sequence":"additional","affiliation":[{"name":"Department of Oncology, Binzhou Medical University Hospital","place":["Binzhou, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-2300","article-title":"Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab","volume":"101","author":"de Filette","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2018-000591","article-title":"Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes","volume":"7","author":"Kotwal","year":"2019","journal-title":"BMJ Open Diabetes Res Care"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2019-00423","article-title":"Checkpoint inhibitor-associated autoimmune diabetes is distinct from type 1 diabetes","volume":"104","author":"Tsang","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2337\/db12-1398","article-title":"Definition of high-risk type 1 diabetes HLA-DR and HLA-DQ types using only three single nucleotide polymorphisms","volume":"62","author":"Nguyen","year":"2013","journal-title":"Diabetes"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1086\/429843","article-title":"Localization of a type 1 diabetes locus in the IL2RA\/CD25 region by use of tag single-nucleotide polymorphisms","volume":"76","author":"Vella","year":"2005","journal-title":"Am J Hum Genet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22042093","article-title":"Immune checkpoint inhibitor-induced diabetes mellitus: potential role of T cells in the underlying mechanism","volume":"22","author":"Mourad","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s12272-010-1115-3","article-title":"Forced expression of programmed death-1 gene on T cell decreased the incidence of type 1 diabetes","volume":"33","author":"Won","year":"2010","journal-title":"Arch Pharm Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2019743117","article-title":"Cytocidal macrophages in symbiosis with CD4 and CD8 T cells cause acute diabetes following checkpoint blockade of PD-1 in NOD mice","volume":"117","author":"Hu","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-020-00443-4","article-title":"Type 1 diabetes mellitus as a disease of the \u03b2-cell (do not blame the immune system?)","volume":"17","author":"Roep","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2020.11.004","article-title":"Incretin response in immune checkpoint inhibitor-induced diabetes: an observational study","volume":"47","author":"Bastin","year":"2021","journal-title":"Diabetes Metab"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13450","article-title":"Two types of fulminant type 1 diabetes mellitus: immune checkpoint inhibitor-related and conventional","volume":"12","author":"Imagawa","year":"2021","journal-title":"J Diabetes Investig"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-0609","article-title":"Immune checkpoint inhibitor-associated diabetes: a single-institution experience","volume":"43","author":"Byun","year":"2020","journal-title":"Diabetes Care"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-020-09618-w","article-title":"Diabetes mellitus induced by immune checkpoint inhibitors: type 1 diabetes variant or new clinical entity? Review of the literature","volume":"22","author":"Lo Preiato","year":"2021","journal-title":"Rev Endocr Metab Disord"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13424","article-title":"Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes","volume":"200","author":"Quandt","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101473","article-title":"Clinical characteristics and outcomes of immune checkpoint inhibitor-induced diabetes mellitus","volume":"24","author":"Liu","year":"2022","journal-title":"Transl Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.968798","article-title":"Characterization of immune checkpoint inhibitor-associated fulminant type 1 diabetes associated with autoantibody status and ethnic origin","volume":"13","author":"Qiu","year":"2022","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14050","article-title":"Immune checkpoint inhibitor-induced type 1 diabetes: a systematic review and meta-analysis","volume":"36","author":"Akturk","year":"2019","journal-title":"Diabetes Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-1465","article-title":"Increased reporting of immune checkpoint inhibitor-associated diabetes","volume":"41","author":"Wright","year":"2018","journal-title":"Diabetes Care"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ando.2018.07.006","article-title":"Expert opinion on immunotherapy induced diabetes","volume":"79","author":"Smati","year":"2018","journal-title":"Ann Endocrinol (Paris)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1530\/EC-18-0068","article-title":"Society for Endocrinology Endocrine Emergency Guidance: acute management of the endocrine complications of checkpoint inhibitor therapy","volume":"7","author":"Higham","year":"2018","journal-title":"Endocr Connect"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094591","article-title":"Tissue-specific methylation of human insulin gene and PCR assay for monitoring beta cell death","volume":"9","author":"Husseiny","year":"2014","journal-title":"PloS One"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-016-3897-4","article-title":"Methylation of insulin DNA in response to proinflammatory cytokines during the progression of autoimmune diabetes in NOD mice","volume":"59","author":"Rui","year":"2016","journal-title":"Diabetologia"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1530\/EC-20-0342","article-title":"Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review","volume":"9","author":"Stelmachowska-Bana\u015b","year":"2020","journal-title":"Endocr Connect"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy162","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Haanen","year":"2018","journal-title":"Ann Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.18.00005","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary","volume":"14","author":"Brahmer","year":"2018","journal-title":"J Oncol Pract"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2016-217454","article-title":"Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma","volume":"2016","author":"Aleksova","year":"2016","journal-title":"BMJ Case Rep"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/dme.15469","article-title":"Exploring the potential role of C-peptide in type 2 diabetes management","volume":"42","author":"Lin","year":"2025","journal-title":"Diabetes Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2023.10.016","article-title":"Clinically approved monoclonal antibodies-based immunotherapy: association with glycemic control and impact role of clinical pharmacist for cancer patient care","volume":"46","author":"Al-Taie","year":"2024","journal-title":"Clin Ther"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000042490","article-title":"Sintilimab-induced diabetes mellitus and thyroid dysfunction in patient with gastric adenocarcinoma: a case report and literature review","volume":"104","author":"Zan","year":"2025","journal-title":"Med (Baltimore)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000035946","article-title":"Sintilimab-related diabetes mellitus and psoriasis: a case report and literature review","volume":"102","author":"Huang","year":"2023","journal-title":"Med (Baltimore)"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1881986\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T08:56:06Z","timestamp":1782896166000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1881986\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":32,"alternative-id":["10.3389\/fendo.2026.1881986"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1881986","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"article-number":"1881986"}}